Fina Biosolutions, LLC is a biotechnology company headquartered in Maryland's biotechnology corridor that manufactures affordable conjugate vaccines for emerging markets. The company provides bioconjugation and protein services, including the production of Protein CRM197, a key component in conjugate vaccine development. It operates as a privately held research and development stage company focused on novel vaccine conjugate commercialization.

Nouveau BioSciences is a biotechnology company pioneering novel drug development technology that leverages high-throughput chemical and genomic screening to create targeted nanomedicines for cancer treatment. The company has entered into multiple licensing agreements with the University of Virginia to expand its pipeline of innovative nanomedicines.

Nostopharma, LLC is a women-owned pharmaceutical company specializing in treatments for bone and connective tissue disorders via precision drug delivery. The company is developing sustained-release, biodegradable nanoparticle delivery systems for soft tissue trauma complications. In 2023, TEDCO invested $250,000 in Nostopharma to advance its orthopedic patient care therapeutics.

Bacteriophage therapy for drug-resistant infections (PhageBank). I-270 corridor.

Adial Pharmaceuticals is a Charlottesville, Virginia-based clinical-stage biopharmaceutical company focused on developing treatments for alcohol use disorder and other addictions. Its lead therapeutic candidate targets the serotonin-3 receptor to reduce alcohol consumption. The company is publicly traded on the Nasdaq under the ticker ADIL.

Advaray (formerly BrachyFoam, Inc.) was an early-stage medical device company based in Charlottesville, Virginia developing devices for cancer therapy applications. The company was a University of Virginia Licensing & Ventures Group startup that was acquired by cancer therapy leader CQ Medical in October 2023.

CAR-T cell therapy (ddCAR / anito-cel for multiple myeloma). I-270 corridor.

Autoimmune therapeutics; lupus nephritis (voclosporin / LUPKYNIS). I-270 corridor.

Avant Genomics is a Charlottesville, Virginia biotechnology company developing a first-of-its-kind platform that automates liquid biopsy sample preparation for blood-based cancer detection and therapeutic monitoring. The company holds exclusive IP developed at the University of Virginia and secured over $3 million in funding in May 2026 to accelerate its automated platform.

BrightSpec is a commercial-stage life science instrumentation company founded in Charlottesville, VA in 2012. It develops instruments based on molecular rotational resonance (MRR) spectroscopy for molecular analysis applications in the pharmaceutical, chemical, and consumer goods industries.

Capsulomics, LLC is a precision medicine startup from Johns Hopkins University focused on the prediction and detection of esophageal cancer. The company is commercializing the EsoCAN assay for esophageal squamous cell carcinoma (ESCC) diagnosis. Capsulomics is developing non-invasive molecular diagnostic solutions for early cancer detection.

mRNA cell therapy (Descartes platform) for autoimmune disease. I-270 corridor.

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, headquartered in Frederick, Maryland. The company is advancing a pipeline of cell therapy candidates targeting serious autoimmune conditions. Cartesian is publicly traded on the Nasdaq exchange.

Contraline is a biotechnology company headquartered in Charlottesville, Virginia, developing male contraceptive products. Founded in 2015 by Kevin Eisenfrats and Dr. John Herr, it is a University of Virginia Licensing & Ventures Group venture. Its products are investigational and have not yet received FDA approval.

CytoRecovery is a Blacksburg, Virginia-based life sciences company developing next-generation cell sorting and recovery technology. Founded from a breakthrough at Virginia Tech, the company commercializes a patented cell-sorting method that is faster and less invasive than existing approaches, with applications in disease research and drug development.

Dionysus Digital Health (also known as Dionysus Healthcare) is a molecular diagnostics company leveraging AI and epigenetics, focused on maternal health. It has developed an epigenetic testing platform designed to predict and diagnose conditions such as postpartum depression before symptoms manifest, and provides personalized stress and wellness feedback.

Emergent BioSolutions is a specialty biopharmaceutical company headquartered in Gaithersburg, Maryland, that develops, manufactures, and delivers medical countermeasures and specialty products protecting against public health threats for both civilian and military populations. The company has operated for more than two decades across intentional and naturally emerging health threats.

EpiEP, Inc. is a medical device company that developed the EpiAccess™ epicardial access system, which is both FDA cleared and CE marked. The system enables physicians to access the space around the heart for electrophysiology procedures and was spun out of the University of Virginia.

HTIC, Inc. is a University of Virginia spin-off biotechnology company focused on developing novel antibody-based biologics for unmet medical needs. The company is developing a humanized monoclonal antibody for the treatment of human diseases associated with dysfunctional immune regulation.

Hyku Biosciences is a precision medicine company developing small molecule therapeutics with novel mechanisms of action to potently inactivate proteins that drive disease progression, with a focus on oncology. The company is headquartered in Virginia and launched in September 2023 with $56 million in seed financing to advance its covalent medicines platform.